Trade name of the drug: Carsil
Drug form: Carsil coated tablets of 22.5 mg; Hard capsules of 90 mg, and hard capsules of 110 mg
One coated tablet contains (mg):
Active substance: Silymarin (as 100%) 22.5 mg, 90 mg and 100 mg.
Additives: Lactose, Wheat starch, Sorbite, Glucose, Microcrystaline cellulose, Talk, Magnesium Stearate, Polyvinylpyrolidone, Sodium bicarbonate.
Lipotropic agent with hepatoprotective action.
Chronic inflammation of liver, hepatic dystrophy; cirrhosis of liver; fatty degeneration due to hepatitis, damage of the liver with functional disorders caused by intoxication; as a prophylactic agent in cases with enhanced intake of substances and drugs overloading the hepatic function.
Hypersensitivity to Silymarin
The drug can be administered only under physician’s supervision during pregnancy and breast feeding period, and only if the drug treatment benefit outweighs the risk of its administration.
No data is available about disorders in driving ability and machine operation in Carsil treated patients.
Administration and Dosage
It is perorally administered: adults 1 – 2 coated tablets, 3 times daily.
In cases of highly disordered hepatic function, the daily dose may be doubled.
The treatment courses last at least 3 months.
Carsil can be prescribed prophylactically – 70 – 100 mg daily.
The daily dose for children is 5 mg/kg body weight, devided into 2 – 3 intakes.
Undesired side effects
Undesired adverse effects necessitating the discontinuation of the treatment have not been observed so far – neither during a short-term high dosage, nor during long-term treatment.
Light laxative and diuretic effect has been observed in some patients.
Some disorders of the vestibular functions and disorders in the digestion can occur or pre-existing ones can be aggravated during long-term treatment with Carsil, which usually abate after discontinuation.
Packages with 80 coated tablets of 22.5 mg; packages of 30 hard hard capsules of 90 mg, and packages of 30 hard capsules of 110 mg.
In original packages. In dry and light-protected place, at a temperature of 15 – 20ºC.
Sopharma AD 16 Iliensko Chosee St, Sofia, Bulgaria.
Carsil intake in adults: As a prophylactic: 2-3 tablets daily. In light and moderately severe cases 1-2 tablets three times daily. In severe forms of illness 2-3 tablets three times daily. Carsil is characterized by a very good resorption and tolerance. No side effects are observed with therapeutic doses.
Package: 80 coated tablets of 35 mg each.
Exerts a specific protective and therapeutic effect on liver cells. Stimulates the cellular metabolism and protects the liver. Has an antioxidant and anti-inflammatory effect.
In chronic liver inflammation, liver dystrophy, cirrhosis, adipose degeneration resulting from hepatitis, liver impairment with functional disorders caused by poisoning, and as a prophylactic agent in cases of an increased inflow of liver function loading substances.
Position of Carsil in the comprehensive therapy of liver cirrhosis
Carsil has a good effect in the therapy of liver cirrhosis, too. The pathological biochemical values become normal in a high percentage of the cases. The above is typical above all for patients in a stage of exacerbation of the disease.
Administered to patients with liver cirrhosis prior to surgery, Carsil exhibits a favorable effect manifested by simulation of the liver functions, which reduces the surgical risk.
Of special importance is the fact that the development of ascites was prevented in decomprensated cirrhosis.
The biopsy follow-up indicates that the activity of the morbific process is reduced even in the majority of the cases with chronic active hepatitis of a considerably poorer prognosis.
The judgment of the effect of Carsil therapy in acute hepatitis is difficult, due to its inclination to spontaneous cure. However, a conclusion may be drawn from the observations so far, that Carsil has a positive effect on therapeutically unfavorable forms of hepatitis, such as the parenterally transmitted hepatitis, and the one with a tendency to cholestasis and retention, i.e. it prevents its transition to a chronic stage. A reduction of the inflammatory activity or retention of the process was found in the biopsy investigations performed.
The electron microscopy investigations show existence of predominantly intact and glycogen-rich liver parenchyma cells after Carsil therapy.
Toxometabolic liver damage
In toxometabolic liver damage by exogenous liver-loading substances (alcohol, drugs), or due to metabolic disorders (diabetes mellitus), the principal finding in the majority of the cases is the adipose of the liver, while the biochemical parameters remain normal or slightly alerted. The pathologically increased values of the transaminases, as well as the bromphthalein test, show a pronounced tendency to normalization, after Carsil therapy.
Some psychopharmacological and anticonvulsive agents are known to be capable of causing liver morphological changes, resulting in intrahepatic cholestasis, which renders their prolonged administration problematic. In patients on psychopharmacological and anticonvulsive, Carsil has had a favorable effect on 73% of the pathologically altered live parameters, with the majority of the latter being normalized.
No adverse reactions of Carsil requiring discontinuation of the therapy have been observed: either with a short-term high dosage, or in a long-lasting therapy.
A week laxative effect (diuretic respectively) was observed in some cases, which was not undesired. Sometimes vestibular disorders occur after Carsil therapy, however they subside with the discontinuation of the drug.
Hypersensitivity to Silymarin.
Administration and Posology
Adults: As a prophylactic: 2-3 tablets daily.In light and moderately severe cases 1-2 tablets three times dailyIn severe forms of illness 2-3 tablets three times daily Usually, 1-2 tablets are orally administered to adults 3 times daily. The daily dose may be doubled in case of severely impaired liver function. The course of therapy should be no less than three months and 70-100 mg daily prescribed for prevention.
Children: The daily dose is 5 mg/kg body mass, divided in 2-3 intakes
35 mg tablets in packs of 80.
At a moderate temperature 60-86°F (15-30°C).
Two (2) years.
Copyright © 2016-2017 BPG Ltd/Biogenic Stimulants, Inc. All rights reserved.